



**WE LEVERAGE CUTTING-EDGE TECHNOLOGIES,
COMBINING BIOTECH AND NUCLEAR INDUSTRIES,
TO DEVELOP BREAKTHROUGH TREATMENTS IN ONCOLOGY.**

Based on its unique expertise in the production of lead-212 and the development of radioligand therapies, Orano Med aims to become the oncology leader in **targeted alpha therapies** to offer innovative solutions for patients with high unmet medical needs.



oranomed
²¹²Pb for Targeted Alpha Therapy

Learn more at

oranomed.com